Secondary Objectives of the APEX COPD Registry Initiative
| Improve quality of care, and primary care patient outcomes through structured COPD support and increased understanding of COPD management |
| Understand the clinical phenotypes of COPD that predict response to or appropriateness of inhaled treatments |
| Understand the current burden and minimize side effects of steroid exposure through use of appropriate treatments |
| Support the development of effective and efficient diagnostic routines and therapeutic principles |
| Assess the level of classification differences as defined by comparing clinician-diagnosed COPD at baseline against established guidelines’ diagnostic criteria |
| Describe disease management patterns such as treatment changes over time (eg, step up, step down, and switches), as well as the reasons for changes and the effect of these changes on disease progression |
| Assess the impact of inhaler technique, inhaler type and lung function on disease management and severity (eg, exacerbations and CAT scores) |
| Describe factors associated with treatment choice at baseline and describe disease progression |
| Describe risk factors (eg, age, sex, smoking, BMI, occupation, family history, presence of comorbidities, socioeconomic status, quality of care, lung function, exacerbations) associated with disease progression, PROs, and healthcare utilization |
| Assess the occurrence of exacerbations and other conditions, including URTIs and seasonal variations |
| Assess biomarker data and estimate their predictive value for disease diagnosis, pheno- and endo-type characterization, response to treatment and disease progression |
| Identify patients who may be eligible for participation in future research studies |
APEX, Advancing the Patient Experience; BMI, body mass index; CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease; PRI/PRO, patient-reported information & outcomes; URTI, upper respiratory tract infection.